Cortical structures are often critically affected by ischemic and trau
matic lesions which may cause transient or permanent functional distur
bances, These disorders consist of changes in the membrane properties
of single cells and alterations in synaptic network interactions withi
n and between cortical areas including large-scale reorganizations in
the representation of the peripheral input. Prominent functional modif
ications consisting of massive membrane depolarizations, suppression o
f intracortical inhibitory synaptic mechanisms and enhancement of exci
tatory synaptic transmission can be observed within a few minutes foll
owing the onset of cortical hypoxia or ischemia and probably represent
the trigger signals for the induction of neuronal hyperexcitability,
irreversible cellular dysfunction and cell death, Pharmacological mani
pulation of these early events may therefore be the most effective app
roach to control ischemia and lesion induced disturbances and to atten
uate long-term neurological deficits. The complexity of secondary stru
ctural and functional alterations in cortical and subcortical structur
es demands an early and powerful intervention before neuronal damage e
xpands to intact regions, The unsatisfactory clinical experience with
calcium and N-methyl-D-aspartate antagonists suggests that this result
might be achieved with compounds that show a broad spectrum of action
s at different ligand-activated receptors, voltage-dependent channels
and that also act at the vascular system. Whether the same therapy str
ategies developed for the treatment of ischemic injury in the adult br
ain may be applied for the immature cortex is questionable, since youn
g cortical networks with a high degree of synaptic plasticity reveal a
different response pattern to hypoxic and ischemic insults. Age-depen
dent molecularbiological, morphological and physiological parameters c
ontribute to an enhanced susceptibility of the immature brain to these
noxae during early ontogenesis and have to be investigated in more de
tail for the development of adequate clinical therapy.